Minsk Clinical Cancer Centerdepartment Of Oncology 1

1. Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial
1